Anavex Life Sciences Corp. $AVXL Position Boosted by Wellington Management Group LLP

Wellington Management Group LLP raised its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 17.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,000 shares of the biotechnology company’s stock after acquiring an additional 28,326 shares during the quarter. Wellington Management Group LLP owned approximately 0.22% of Anavex Life Sciences worth $1,604,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. E Fund Management Co. Ltd. purchased a new position in Anavex Life Sciences during the 1st quarter valued at about $102,000. Nuveen LLC purchased a new position in Anavex Life Sciences during the 1st quarter valued at about $1,622,000. Swiss National Bank bought a new stake in shares of Anavex Life Sciences in the 1st quarter valued at approximately $1,411,000. Vanguard Group Inc. grew its stake in shares of Anavex Life Sciences by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 4,902,246 shares of the biotechnology company’s stock valued at $42,061,000 after buying an additional 221,802 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in Anavex Life Sciences by 20.9% in the first quarter. PNC Financial Services Group Inc. now owns 57,673 shares of the biotechnology company’s stock worth $495,000 after buying an additional 9,966 shares during the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Stock Performance

AVXL opened at $9.64 on Friday. The business has a 50 day moving average price of $10.53 and a 200 day moving average price of $9.25. Anavex Life Sciences Corp. has a twelve month low of $4.93 and a twelve month high of $14.44. The firm has a market cap of $827.98 million, a P/E ratio of -16.91 and a beta of 0.80.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, analysts anticipate that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on AVXL. HC Wainwright restated a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a report on Friday, August 22nd. Wall Street Zen downgraded Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 23rd. Finally, D. Boral Capital restated a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $44.00.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.